Estradiol Gel (Divigel/Elestrin) vs Duavee: A Real Side-Effect Comparison for Menopausal Women

What These Two Therapies Are and How They Differ

Estradiol gel and Duavee are both approved by the FDA for moderate-to-severe vasomotor symptoms (hot flashes, night sweats) in menopause, but they belong to different drug classes and require different management.

Estradiol gel delivers bioidentical 17-beta estradiol through the skin. Divigel 0.1% is applied as a single-dose packet to the upper thigh; Elestrin 0.06% uses a metered-pump system applied to the upper arm. Both bypass first-pass liver metabolism, which has real implications for your clot risk and triglyceride levels. If your uterus is intact, you must add a progestin, because unopposed estrogen stimulates the endometrium and raises uterine cancer risk.

Duavee is a tissue-selective estrogen complex (TSEC). It pairs conjugated estrogens (CE) 0.45 mg with bazedoxifene 20 mg, a selective estrogen-receptor modulator (SERM) that acts as an estrogen antagonist in the uterus and breast while allowing CE to work in the brain, bone, and vasculature. Because bazedoxifene handles endometrial protection, Duavee requires no progestin, even in women with an intact uterus. That is its defining feature.

The Core Pharmacological Difference

The gel delivers estradiol, the dominant estrogen your ovaries made during your reproductive years. Duavee delivers conjugated estrogens, a mixture of equine-derived estrogen sulfates (estrone sulfate, equilin sulfate, and others). These are structurally different from 17-beta estradiol, and their receptor-binding profiles differ slightly, though both effectively treat vasomotor symptoms.

Why the Route of Administration Changes the Risk Profile

Transdermal delivery avoids the liver's first-pass metabolism. Oral estrogens amplify hepatic production of clotting factors and C-reactive protein; transdermal estradiol does not trigger this to the same degree. Duavee is an oral tablet, so its CE component passes through the liver. This distinction drives meaningful differences in VTE and triglyceride risk between the two options, covered in detail below.

Side-Effect Profile: Estradiol Gel

Transdermal estradiol gel's side-effect pattern reflects both its delivery method and its estrogen-only formulation (when used alone or paired with a separate progestin).

Skin and Application-Site Reactions

The most common gel-specific side effect is local skin irritation at the application site: redness, itching, or mild rash. In clinical data for Divigel, application-site reactions occurred in approximately 5 to 7% of users, usually mild and self-limiting. Rotating the application site and letting the gel dry completely before dressing reduces this. Accidental transfer to a partner or child through skin contact is a real concern; the gel must dry before contact.

Estrogen-Class Side Effects

These occur regardless of delivery route and reflect estrogen's systemic action:

• Breast tenderness or fullness (common in the first 1 to 3 months)
• Nausea (less frequent than with oral estrogen because serum peaks are lower)
• Headache or migraine, particularly in the first cycle
• Vaginal discharge or spotting (especially if progestin cycling produces withdrawal bleeds)
• Fluid retention and bloating

Breast tenderness often resolves after the first 2 to 3 months. If it persists, a dose reduction from 0.1% to 0.0625% (mid-range Divigel packet) may help without sacrificing full symptom control.

Progestin Add-On Side Effects

Because gel users with an intact uterus must take a progestin, they carry an additional side-effect burden from that agent. Micronized progesterone (Prometrium 100 to 200 mg nightly) generally produces fewer mood and libido side effects than synthetic progestins like medroxyprogesterone acetate (MPA), though it may cause drowsiness. Women who switch from MPA to micronized progesterone when using estradiol gel sometimes report improved mood, sleep, and sexual interest, though head-to-head randomized trial data specifically in gel users is limited. This is an area where evidence is partly extrapolated from broader MHT trials rather than gel-specific studies.

VTE Risk with Transdermal Estradiol

This is where transdermal gel carries a meaningful advantage over oral therapies. A large pharmacoepidemiological study found that transdermal estradiol was not associated with an increased risk of VTE, whereas oral estrogen was associated with an approximately two-fold increased risk. For women with a personal or family history of clots, obesity (BMI <30 and above), or thrombophilia, transdermal delivery is the preferred route per current evidence, and estradiol gel fits that need.

Triglycerides and Liver Enzymes

Transdermal estradiol has a neutral to mildly favorable effect on triglycerides and does not significantly increase sex hormone-binding globulin (SHBG), which matters for women with hypertriglyceridemia or those on thyroid replacement (high SHBG can bind thyroid hormone and alter levothyroxine requirements).

Side-Effect Profile: Duavee (CE/Bazedoxifene)

Duavee's side-effect profile comes from three sources: the CE component (estrogen effects), the bazedoxifene component (SERM effects), and the interaction between the two.

Hot Flush Paradox: Initial Flare

Some women experience a brief increase in hot flashes in the first few weeks after starting bazedoxifene, consistent with SERM class effects. This is temporary. In the SMART-1 trial, CE 0.45 mg/bazedoxifene 20 mg significantly reduced the mean number of moderate-to-severe hot flushes compared with placebo at 12 weeks, confirming that this initial period gives way to meaningful symptom relief.

Gastrointestinal Side Effects

Duavee is an oral tablet, and gastrointestinal effects are more prominent than with transdermal gel:

• Nausea: reported in approximately 9% of users in SMART trials
• Dyspepsia and abdominal pain
• Diarrhea (less common)

Taking Duavee with food substantially reduces nausea. The prescribing information specifies it should not be taken with grapefruit juice, which inhibits CYP3A4 and can raise bazedoxifene exposure.

Muscle Spasms and Musculoskeletal Effects

Muscle spasms were reported in 9.5% of women taking CE 0.45 mg/bazedoxifene 20 mg in the SMART trials, compared with 6.6% in the placebo group. This side effect is uncommon with transdermal estradiol and appears to be bazedoxifene-related. For women with baseline musculoskeletal complaints, fibromyalgia, or those returning to exercise in perimenopause recovery, this warrants a conversation before starting.

No Withdrawal Bleeds

One of Duavee's genuine advantages: because bazedoxifene suppresses endometrial proliferation rather than cycling it, most women on Duavee have no scheduled withdrawal bleeds. Any vaginal bleeding on Duavee is unexpected and requires evaluation. This is often cited as a quality-of-life benefit over progestin-cycling regimens.

VTE Risk with Oral CE

Because Duavee contains oral CE, the hepatic first-pass effect applies. The current evidence does not establish that bazedoxifene abolishes the VTE risk associated with oral CE. Bazedoxifene does not appear to worsen VTE risk beyond CE alone, and in some analyses the combination may be neutral, but it does not achieve the low VTE profile of transdermal delivery. Women with elevated VTE risk should discuss this difference with their clinician before choosing Duavee.

Breast Effects: A Key Differentiator

Duavee was specifically designed to limit estrogenic stimulation of breast tissue. Bazedoxifene acts as an estrogen antagonist in the breast, and the SMART program assessed breast outcomes carefully. In the SMART-2 and SMART-3 trials, CE/bazedoxifene was associated with breast tenderness rates similar to or lower than placebo, and no clinically significant increase in mammographic breast density. This stands in notable contrast to progestin-containing regimens, where breast tenderness and increased breast density are well-established effects.

For women with dense breasts, a personal history of bothersome breast tenderness on prior hormone therapy, or anxiety about mammographic density affecting cancer screening, Duavee's breast profile may be its most compelling advantage over gel-plus-progestin. Estradiol gel alone (without progestin) has a lower breast tenderness burden than gel-plus-progestin, but the endometrial protection requirement for uterus-intact women means the progestin is not optional.

Lipid Effects of Duavee

As an oral estrogen-containing product, CE in Duavee raises HDL and lowers LDL, which sounds beneficial, but it also raises triglycerides. Women with pre-existing hypertriglyceridemia (levels above 400 mg/dL) should not use any oral estrogen, including Duavee. Estradiol gel is the safer choice in that context.

Bone Density: A Meaningful Difference

Both options protect bone, but with different evidence bases.

Transdermal estradiol gel preserves bone mineral density (BMD) at the spine and hip. The dose-response is well established: standard doses used for vasomotor symptom control (0.05 to 0.1 mg/day estradiol equivalents) are generally adequate for BMD preservation in early postmenopause.

The SMART trials demonstrated that CE 0.45 mg/bazedoxifene 20 mg significantly preserved lumbar spine and total hip BMD compared with placebo over 12 to 24 months. Bazedoxifene was originally developed as a standalone treatment for osteoporosis in postmenopausal women, so its bone effects are well-studied and its contribution to Duavee's skeletal protection is real, not incidental.

For women in early postmenopause with osteopenia or osteoporosis concerns, Duavee may offer a marginal advantage from the dual mechanism (CE plus bazedoxifene SERM activity at bone), though a direct randomized comparison against transdermal estradiol for BMD preservation does not exist. This is a data gap worth naming plainly.

Who This Is Right For (and Who It Is Not)

Choosing between these two therapies is rarely a question of which is globally "better." It is a question of match.

Estradiol Gel Is Likely the Better Fit If You:

• Have a history of or elevated risk for VTE (clots in leg or lung)
• Have hypertriglyceridemia
• Have migraines that worsen with oral estrogen's fluctuating serum peaks
• Prefer bioidentical 17-beta estradiol over conjugated estrogens
• Had breast tenderness or mood symptoms on a prior progestin and want to try micronized progesterone instead
• Have had a hysterectomy (can use gel without any progestin, simplifying the regimen)
• Are in perimenopause and not yet fully postmenopausal (Duavee is approved for postmenopausal women only)

Duavee Is Likely the Better Fit If You:

• Have an intact uterus and want to avoid progestin entirely
• Had significant mood, bloating, or breast tenderness attributed to progestins on prior MHT
• Have dense breasts and want to minimize additional mammographic density
• Prefer one tablet to a gel-plus-pill regimen
• Have no contraindication to oral estrogen and are comfortable with a slightly higher VTE baseline vs. Transdermal

Who Should Not Use Either Without Specialist Input:

• Personal history of estrogen-receptor-positive breast cancer (both are contraindicated or require careful specialist review)
• Active or recent VTE (oral therapy contraindicated; transdermal discussed case by case)
• Active liver disease or gallbladder disease
• Women with a BMI above 40 who have additional VTE risk factors (transdermal preferred but individual assessment needed)
• Women with unexplained vaginal bleeding prior to starting therapy

Pregnancy, Lactation, and Contraception

Both estradiol gel and Duavee are contraindicated in pregnancy. Estrogen exposure in early pregnancy has been associated with fetal harm, and bazedoxifene's SERM activity carries additional theoretical teratogenic risk. Neither drug has an established safe dose in human pregnancy.

Most women starting menopausal hormone therapy are in perimenopause or postmenopause, but perimenopause does not mean pregnancy is impossible. Ovulation can still occur during perimenopause, sometimes unpredictably. If you are in perimenopause and not yet 12 consecutive months without a period, pregnancy remains biologically possible.

If you are perimenopausal and sexually active with a possibility of conception, use reliable contraception while on either of these therapies. Low-dose combined oral contraceptives are sometimes used in perimenopause for both contraception and symptom control, though they differ from MHT. Discuss the overlap with your clinician.

Estradiol gel is not studied in lactating women. Estrogen suppresses milk production and should generally be avoided during breastfeeding. Duavee has no established safety data in lactation, and the presence of bazedoxifene (a SERM with receptor-modulating properties) makes caution even more appropriate. Neither is recommended during breastfeeding.

The Evidence Gap: What the Data Does Not Tell Us

Women have been historically underrepresented in large cardiovascular and oncology trials. A few honest limitations apply here:

There is no published randomized head-to-head trial directly comparing estradiol gel with Duavee for any outcome, including side effects. The comparison in this article is synthesized across separate trial programs and pharmacoepidemiological data, not a single study.

The SMART trials enrolled predominantly white, postmenopausal women aged 40 to 75 with an intact uterus. How Duavee's side-effect profile translates across racial and ethnic groups, body size ranges, or in women with comorbidities is less certain.

Long-term breast cancer safety data for the CE/bazedoxifene combination beyond five years is not yet available from randomized trials. The Women's Health Initiative (WHI) data does not apply directly to Duavee, because WHI used CE 0.625 mg plus MPA, a progestin that carries different breast-tissue effects than bazedoxifene.

Estradiol gel is widely used but the majority of its VTE safety evidence comes from observational studies, not randomized trials. The causal inference is strong, but it is observational data, not an RCT.

Practical Considerations: Dosing, Cost, and Coverage

Divigel comes in three packet sizes: 0.25 g (0.25 mg estradiol), 0.5 g (0.5 mg), and 1.0 g (1.0 mg). Standard starting doses are 0.25 mg to 0.5 mg per day, applied to the upper thigh. Elestrin delivers 0.52 mg estradiol per pump actuation, with the starting dose typically one pump (0.52 mg) per day to the upper arm.

Duavee is a fixed-dose combination: one tablet of CE 0.45 mg/bazedoxifene 20 mg per day. There is no dose titration option, which is a limitation if you need a lower estrogen dose.

Generic transdermal estradiol gel options exist, making gel generally less expensive than Duavee, which as of 2025 remains brand-only. Insurance coverage varies. Both require a prescription.

Monitoring and Follow-Up

For estradiol gel users: annual breast exam, mammography per standard screening guidelines, endometrial surveillance if breakthrough bleeding occurs (particularly relevant if the progestin dose or type is changed), and periodic lipid and thyroid panels if you are on levothyroxine (estrogen can raise SHBG and alter free T4 levels).

For Duavee users: mammography per guidelines, prompt evaluation of any vaginal bleeding (bazedoxifene suppresses endometrial proliferation, so any bleeding is unexpected and warrants workup), and lipid monitoring if triglycerides were borderline at baseline.

Both therapies are typically reassessed at 3 months after starting to evaluate symptom control and tolerability, then annually per The Menopause Society's 2023 position statement on menopausal hormone therapy.